Literature DB >> 15216943

In-vitro activity of nisin against clinical isolates of Clostridium difficile.

A Bartoloni1, A Mantella, B P Goldstein, R Dei, M Benedetti, S Sbaragli, F Paradisi.   

Abstract

Nisin is a cationic peptide produced by Lactococcus lactis. Its activity against clinical isolates of Clostridium difficile was compared to that of vancomycin and metronidazole by minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC) and time-kill studies. Nisin was more active than the other agents, with a MIC90 of 0.256 mg/L and strong bactericidal activity. Nisin may be a promising agent for the management of C. difficile associated diarrhea.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15216943     DOI： 10.1179/joc.2004.16.2.119

Source DB:  PubMed          Journal:  J Chemother        ISSN： 1120-009X            Impact factor:   1.714


  21 in total

1.  Clostridium difficile carriage in elderly subjects and associated changes in the intestinal microbiota.

Authors:  Mary C Rea; Orla O'Sullivan; Fergus Shanahan; Paul W O'Toole; Catherine Stanton; R Paul Ross; Colin Hill
Journal:  J Clin Microbiol       Date:  2011-12-07       Impact factor: 5.948

2.  The ABC transporter AnrAB contributes to the innate resistance of Listeria monocytogenes to nisin, bacitracin, and various beta-lactam antibiotics.

Authors:  Barry Collins; Nicola Curtis; Paul D Cotter; Colin Hill; R Paul Ross
Journal:  Antimicrob Agents Chemother       Date:  2010-07-19       Impact factor: 5.191

3.  Overexpression, purification and crystallization of the response regulator NsrR involved in nisin resistance.

Authors:  Sakshi Khosa; Astrid Hoeppner; Diana Kleinschrodt; Sander H J Smits
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2015-09-23       Impact factor: 1.056

4.  Thuricin CD, a posttranslationally modified bacteriocin with a narrow spectrum of activity against Clostridium difficile.

Authors:  Mary C Rea; Clarissa S Sit; Evelyn Clayton; Paula M O'Connor; Randy M Whittal; Jing Zheng; John C Vederas; R Paul Ross; Colin Hill
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-30       Impact factor: 11.205

5.  Evaluation of a nisin-eluting nanofiber scaffold to treat Staphylococcus aureus-induced skin infections in mice.

Authors:  Tiaan D J Heunis; Carine Smith; Leon M T Dicks
Journal:  Antimicrob Agents Chemother       Date:  2013-06-03       Impact factor: 5.191

6.  Synergistic effect between colistin and bacteriocins in controlling Gram-negative pathogens and their potential to reduce antibiotic toxicity in mammalian epithelial cells.

Authors:  Karim Naghmouchi; John Baah; Didier Hober; Eric Jouy; Cédric Rubrecht; Famara Sané; Djamel Drider
Journal:  Antimicrob Agents Chemother       Date:  2013-04-09       Impact factor: 5.191

7.  In vitro and In vivo Antibacterial Effects of Nisin Against Streptococcus suis.

Authors:  Haodan Zhu; Lixiao Han; Yanxiu Ni; Zhengyu Yu; Dandan Wang; Junming Zhou; Bin Li; Wei Zhang; Kongwang He
Journal:  Probiotics Antimicrob Proteins       Date:  2021-01-06       Impact factor: 4.609

8.  Nisin/polyanion layer-by-layer films exhibiting different mechanisms in antimicrobial efficacy.

Authors:  Hanan Fael; A Levent Demirel
Journal:  RSC Adv       Date:  2020-03-11       Impact factor: 4.036

9.  Activate to eradicate: inhibition of Clostridium difficile spore outgrowth by the synergistic effects of osmotic activation and nisin.

Authors:  Michelle M Nerandzic; Curtis J Donskey
Journal:  PLoS One       Date:  2013-01-22       Impact factor: 3.240

10.  Saturation mutagenesis of lysine 12 leads to the identification of derivatives of nisin A with enhanced antimicrobial activity.

Authors:  Evelyn M Molloy; Des Field; Paula M O' Connor; Paul D Cotter; Colin Hill; R Paul Ross
Journal:  PLoS One       Date:  2013-03-11       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.